

Type 1 Diabetes Market Size to Reach USD 9.6 billion by 2035 | Epidemiology, Treatment, Trends & Rising Incidence

The report provides a detailed analysis of the current type 1 diabetes marketed drugs and late-stage pipeline drugs, advancements in treatment.

BROOKLYN, NY, UNITED STATES, June 17, 2025 /EINPresswire.com/ -- How big is the market for type 1 diabetes?

The [type 1 diabetes market size](#) reached a value of USD 5.9 billion across the top 7 markets (US, EU4, UK, and Japan) in 2024. Looking forward, IMARC Group expects the top 7 major markets to reach USD 9.6 billion by 2035, exhibiting a growth rate (CAGR) of 4.65% during 2025-2035.



Type 1 Diabetes Market Size to Reach USD 9.6 billion by 2035 | Epidemiology, Treatment, Trends & Rising Incidence

The Type 1 diabetes market in 2025 is a significantly different one than before due to increasing diagnoses, changing models of treatment, and new technology. Type 1 diabetes is a chronic condition where a person's immune system kills off insulin creating cells, necessitating lifelong insulin administration. With an increasing patient population, the market is shifting to ease disease management and provide better outcomes.

Increasing Patient Numbers and Demographics

New cases of Type 1 diabetes are increasingly being diagnosed, especially in older children and young adults. While the causes are multifactorial, some experts suggest a combination of a genetic history, certain environmental factors, and even some activities in early life. The end result is many families grappling with complicated systems of education, access to insulin, and long term surveillance. More effective awareness and education programs are enabling earlier recognition of Type 1 Diabetes, which in turn allows for timely intervention and lessened early complications. An increasing number of patients is directly proportional to the increased requirement of insulin delivery systems, glucose monitoring devices, and comprehensive care

services.

Request a PDF Sample Report: <https://www.imarcgroup.com/type-1-diabetes-market/requestsampl>

Shifting Treatment Landscape

In 2025, insulin therapy continues to be critically important. However, the industry is moving towards more precise and easier to use options. Latest insulin analogs which are rapid-acting and ultra-long-acting mimic natural insulin secretion more closely and lower glucose variability. Their flexibility and safety makes them more preferred and widely available now. At the same time, hybrid closed-loop insulin delivery systems also called "artificial pancreas" are gaining more popularity. These systems reduce the workload for patients as they automatically adjust insulin delivery based on trends from continuous glucose monitoring (CGM) and as a result, diabetes control becomes tighter.

Another important development is the emergence of smart insulin pens. These devices log the dose timing and quantity and synchronize with smartphone applications. Through monitoring dosing patterns, these smart pens help patients and healthcare providers to refine therapy and prevent missed or duplicate doses. Smart pens not only provide convenience but also assist in managing long-term health outcomes through data-driven insights.

Advances in Technology Shaping 2025

The current backbone of market innovation in the care of Type 1 diabetes is Technology. Development of continuous glucose monitors (CGMs) have made them more accurate, smaller, and able to last longer. With some sensors now able to function for up to 14 days without fingerstick tests in normal conditions, the need for user compliance is greatly reduced. Improved user experience as well as CGM accuracy is leading to CGMs improved uptake . They are also integrated into insulin pumps and digital dashboards, which provides a more comprehensive view of glucose trends and allows proactive adjustments.

Development of closed loop systems has not stagnated. Next generation models reduce alerts, make the first time setup easier, and extend the duration between sensor changes. Automation become more accessible not only to older adults and children, but to a wider demographic. The expanding availability of these hybrid systems demonstrates their clear benefits to patients.

Digital health is another area of major growth. Apps and telehealth platforms can now provide real-time coaching, remote data sharing with providers, nutritional guidance, and even psychological support. Predictive analytics powered by AI can estimate whether blood sugar would drop or raise, enabling corrective actions to be taken beforehand. These new layers of technology are enhancing personalization, interaction, and collaboration in care.

Buy Type 1 Diabetes Epidemiology Report -

<https://www.imarcgroup.com/checkout?id=7905&method=809>

The report also provides a detailed analysis of the current type 1 diabetes marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

Competitive Landscape

The competitive landscape of the type 1 diabetes market has been studied in the report with the detailed profiles of the key players operating in the market.

MannKind Corporation

Eli Lilly and Company

Sanofi

AstraZeneca

Oramed Pharmaceuticals

ImCyse

Dompe Farmaceutici

Novo Nordisk

Vertex Pharmaceuticals

7 Major Countries Covered

United States

Germany

France

United Kingdom

Italy
Spain
Japan

Elena Anderson
IMARC Services Private Limited
+1 631-791-1145
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/823008195>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.